Successful treatment of angiomatosis with thalidomide and interferon α. A description of five cases and overview of treatment of angiomatosis and proliferating hemangiomas;Úspěšná léčba angiomatózy thalidomidem a interferonem α. Popis pěti pří padů a přehled léčby angiomatózy a proliferujících hemangiomů

Vnitrni Lekarstvi

Volumn 56, Issue 8, 2010, Pages 810-823

  Adam, Z ^a   Pour, L ^a   Krejci M ^a   Pourova E ^b   Synek, O ^b   Zahradova L ^a   Navratil M ^a   Mechl, M ^a   Nebesky T ^a   Neubauer, J ^a   Feit, J ^a   Vokurkova J ^a   Kral Z ^a   Bednarik O ^a   Slampa P ^a   Dolezalova H ^a   Hajek R ^a   Mayer, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b Interní Odd lení Nemocnice Vy kov   (Czech Republic)

Author keywords

Angiodysplasia; Angiomatosis; Antiangiogenic treatment; Bevacizumab; Hemangioma; Hemangiomatosis; Interferon ; Lenalidomide; Lymphangioma; Monoclonal gammopathy; Radiotherapy; Thalidomide; Vascular malformation; Zoledronate

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; THALIDOMIDE;

ADULT; AGED; CASE REPORT; FEMALE; HEMANGIOMA; HEMANGIOMATOSIS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; REVIEW;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANGIOMATOSIS; FEMALE; HEMANGIOMA; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; THALIDOMIDE;

EID: 77956573494     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Weiss SW, Goldblum J, Enzinger FM et al. Hemangiomas and angiomatosis. In: Christopher DM, Krishnan UK, Fredrik M (eds). WHO classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press 2002: 161-168.
2. Adam Z, Křikavová L, Krejčí M et al. Léčba mnohočetné angiomatózy postihující skelet, břišní i hrudní dutinu interferonem alfa, thalidomidem a zoledronatem. Vnitř Lék 2008; 54: 653-664.
3. Sundine MJ, Wirth GA. Hemangiomas: an overview. Clin Pediatr (Phila) 2007; 46: 206-221.
4. Argenta LC, David LR, Sanger C et al. Advances in hemangioma evaluation and treatment. J Craniofac Surg 2006; 17: 748-755.
5. Werner JA, Eivazi B, Folz BJ et al. State of art zur Klassifikation, diagnostik und therapie von zervikofazialen Hämangiomen und vaskulären Malformationen. Laryngo-Rhino-Otol 2006; 85: 883-891. (Pubitemid 46031214)
6. Srbová J. Hemangiomatóza. Sestra 2005; 15: 46.
7. Metry DW, Hawroth A, Altman C et al. Association of solitary, segmental hemangiomas of the skin with visceral hemangiomatosis. Arch Dermatol 2004; 140: 591-596.
8. Vevaina JR, Mark EJ. Thoracic hemangiomatosis masquerading as interstitial lung disease. Chest 1988; 93: 657-659.
9. Sullivan A, Chmura K, Cool CD et al. Pulmonary capillary hemangiomatosis: an immunohistochemical analysis of vascular remodeling. Eur J Med Res 2006; 11: 187-193.
10. Cioffi U, De Simone M, Pavoni M et al. Pulmonary capillary hemangiomatosis in an asymptomatic elderly patient. Int Surg 1999; 84: 168-170.
11. Fugo K, Matsuno Y, Okamoto K et al. Solitary capillary hemangioma of the lung: report of 2 resected cases detected by high-resolution CT. Am J Surg Pathol 2006; 30: 750-753.
12. Ito K, Ichiki T, Ohi K et al. Pulmonary capillary hemangiomatosis with severe pulmonary hypertension. Circ J 2003; 67: 793-795.
13. Levy AD, Abbott RM, Rohrmann CA Jr et al. Gastrointestinal hemangiomas: imaging findings with pathologic correlation in pediatric and adult patients. AJR Am J Roentgenol 2001; 177: 1073-1081.
14. Lyon DT, Mantia AG. Large-bowel hemangiomas. Dis Colon Rectum 1984; 27: 404-414.
15. Park DD, Ricketts RR. Infantile gastrointestinal hemangioma as a cause of chronic anemia. South Med J 1992; 85: 201-205.
16. Mills CS, Lloyd TV, van Aman ME et al. Diffuse hemangiomatosis of the colon. J Clin Gastroenterol 1985; 7: 416-421.
17. Mottl H, Koutecký J, Buncová M et al. Sdruž ený výskyt preaurikulárního hemangiomu s hemangiomatózou tenkého střeva a mesenteria. Čes Slov Pediatr 1985; 40: 523-526.
18. Lakhkar B, Abubacker S. Duodeno-jejunal hemangiomatosis. Indian J Pediatr 2000; 67: 931-933.
19. Djouhri H, Arrive L, Bouras T et al. Diffuse cavernous hemangiomatosis of the rectosigmoid colon: imaging findings. J Comput Assist Tomogr 1998; 22: 851-855.
20. Dobozi BM, Rockey DC. Diffuse colonic hemangiomatosis. Gastrointest Endosc 2004; 60: 799.
21. Elsayes KM, Menias CO, Dillman JR et al. Vascular malformation and hemangiomatosis syndromes: spectrum of imaging manifestations. AJR Am J Roentgenol 2008; 190: 1291-1299.
22. Hsu RM, Horton KM, Fishman EK. Diffuse cavernous hemangiomatosis of the colon: findings on three-dimensional CT colonography. AJR Am J Roentgenol 2002; 179: 1042-1044.
23. Scafidi DE, McLeary MS, Young LW. Diffuse neonatal gastrointestinal hemangiomatosis. CT finding. Pediatr Radiol 1998; 28: 512-518.
24. Schulze PJ, Langendorff G. Extensive, diffuse haemangiomatosis of the skeleton. Rofo 1979; 131: 67-71.
25. Seelhoff A, Schumacher B. 72-year-old woman with anemia and suspected intestinal blood loss. Dtsch Med Wochenschr 2009; 134: 1819-1820.
26. Parker WT, Harper JG, Rivera DE et al. Mesenteric cavernous hemangioma involving small bowel and appendix: a rare presentation of a vascular tumor. Am Surg 2009; 75: 811-816.
27. Marinis A, Kairi E, Theodosopoulos T et al. Right colon and liver hemangiomatosis: a case report and a review of the literature. World J Gastroenterol 2006; 12: 6405-6407.
28. Ibarguen E, Sharp HL, Snyder CL et al. Hemangiomatosis of the colon and peritoneum: case report and management discussion. Clin Pediatr (Phila) 1988; 27: 425-430.
29. Bláhová K, Mottl M, Tůma S. Hemangiomatóza jater u tříměsíčního kojence. Čes Slov Pediatr 1991; 46: 434-436.
30. Moon WS, Yuy HC, Lee JM et al. Diffuse hepatic hemangiomatosis in an adult. J Korean Med Sci 2000; 15: 471-474.
31. Langer C, Thonhofer R, Hagenbarth K et al. Difuse Hämangiomatose von Leber und Milz bei Erwachsenen. Pathologie 2001; 22: 424-428.
32. Kalousová J. Komplexní léčba hemangiomatózy jater. Čes Slov Pediatr 1994; 49: 698-699.
33. Kim JD, Chang UI, Yang JM Clinical challenges and images in Gl. Diffuse hepatic hemangiomatosis involving the entire liver. Gastroenterology 2008; 134: 1830, 2197.
34. D'Antonio A, Boscaino A, de Dominicis G et al. Splenic hemangiomatosis. A report of two cases and review of literature. Adv Clin Path 2002; 6: 119-124.
35. Kairi-Vassilatou E, Grapsa D, Kontogianni-Katsarou K et al. Clinicopathological features of unusual vascular lesions of the pelvis, retroperitoneum and colon in females: a report of five cases and review of the literature. Eur J Gynaecol Oncol 2006; 27: 250-255.
36. Dixit VK, Sharma H, Ratnakar KS. Splenic hemangiomatosis with osseous involvement. Indian J Gastroenterol 1993; 12: 105-106.
37. Lin CH, Hsieh HF, Yu JC et al. Spontaneous rupture of a large exogastric hemangioma. complicated by hemoperitoneum and sepsis. J Formos Med Assoc 2006; 105: 1027-1030.
38. Valentini V, Nicolai G, Lorè B et al. Intraosseous hemangiomas. J Craniofac Surg 2008; 19: 1459-1464.
39. Plowman PN. Skeletal haemangiomatosis presenting with spinal cord compression - postoperative management of progressive disease. Br J Radiol 1997; 70: 429-431.
40. Bandiera S, Gasbarrini A, De Iure F et al. Symptomatic vertebral hemangioma: the treatment of 23 cases and a review of the literature. Chir Organi Mov 2002; 87: 1-15.
41. Janecek M, Dufek P. Generalized hemangiomatosis in relation to the synovial membrane. Acta Chir Orthop Traumatol Cech 1985; 52: 155-160.
42. Dufau JP, le Tourneau A, Audouin J et al. Isolated diffuse hemangiomatosis of the spleen with Kasabach-Merrit-like syndrome. Histopathology 1999; 35: 337-344.
43. Lantuéjoul S, Sheppard MN, Corrin B et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30: 850-857.
44. Junquera F, Saperas E, de Torres I et al. Increased expression of angiogenic factors in human colonic dysplasia. Am J Gastroenterol 1999; 94: 1070-1076.
45. Cirulli A, Liso A, D'Ovidio F et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003; 110: 29-32.
46. Ozawa CR, Banfi A, Glazer NL et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004; 113: 516-527.
47. Lee RJ, Springer ML, Blanco-Bose WE et al. VEGF gene delivery do myocardium: deleterious effects of unregulated expression. Circulation 2000; 102: 898-901.
48. Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy 2006; 38: 1036-1039.
49. Vase P. Estrogen treatment of hereditary hemorrhatic telangiectasia. A double blind controlled trial. Acta Med Scand 1981; 209: 393-396.
50. Junquera F, Feu F, Papo M et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001; 121: 1073-1079.
51. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997; 350: 1445-1446.
52. Pérez-Encinas M, Rabuñal Martínez MJ, Bello López JL. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorhagic telangiectasia? Haematologica 2002; 87: 34-35.
53. Bauditz J, Schachschal G, Wedel S et al. Thalidomie for treatment of severe intestinal bleeding. Gut 2004; 53: 609-612.
54. Bauditz J. Angiogeneseinhibitoren zur Behandlung Angiodysplasie assoziirter gastrointestinaler Blutungen. Dtsch Med Wochenschr 2009; 134: 1893-1896.
55. Madhusudan S, Deplanque G, Braybrooke JP et al. Antiangiogenic therapy for Hippel Lindau disease. JAMA 2004; 291: 943-944.
56. Mahajan D, Miller C, Hirose K et al. Incidental reduction of the size of liver hemangioma following use of VEGF inhibitor bevacizumab. J Hepatol 2008; 49: 867-870.
57. Šlampa P, Petera J et al. Radiační onkologie. Praha: Galén 2007, 30-32, 418-419.
58. Blei F, Orlow SJ, Geronemus R. Multimodal management of diffuse neonatal hemangiomatosis. J Am Acad Dermatol 1997; 37: 1019-1021.
59. Gozal D, Saad N, Bader D et al. Diffuse neonatal haemangiomatosis: successful management with high dose corticosteroids. Eur J Pediatr 1990; 149: 321-324.
60. Hasan Q, Tan ST, Gush J et al. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics 2000; 105: 117-120.
61. Haxhija EQ, Lackner H, Hollwarth ME. Medical treatment of children with hemangiomas and its limitations. Handchir Mikrochir Plast Chir 2009; 41: 78-82.
62. Mulliken JB, Boon LM, Takahashi K et al. Pharmacologic therapy for endangering hemangiomas. Curr Opin Dermatol 1995; 2: 109-113.
63. Musumeci ML, Schlecht K, Perrotta R et al. Management of cutaneous hemangiomas in pediatric patients. Cutis 2008; 81: 315-322.
64. Roganovic J. An update on the treatment of high-risk hemangiomas in infants. Eur J Pediatr Surg 2007; 17: 147.
65. Uysal KM, Olgun N, Erbay A et al. High dose oral methylprednisolone therapy in childhood hemangiomas. Pediatr Hematol Oncol 2001; 18: 335-341.
66. Wilson MW, Hoehn ME, Haik BG et al. Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit. Ophthalmology 2007; 114: 1007-1011.
67. Drucker AM, Pope E, Mahant S et al. Vincristine and corticosteroids as first-line treatment of Kasabach-Merritt syndrome in kaposiform hemangioendothelioma. J Cutan Med Surg 2009; 13: 155-159.
68. Gottschling S, Schneider G, Meyer S et al. Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer 2006; 46: 239-242.
69. Hara K, Yoshida T, Kajiume T et al. Successful treatment of Kasabach-Merritt syndrome with vincristine and diagnosis of the hemangioma using three-dimensional imaging. Pediatr Hematol Oncol 2009; 26: 375-380.
70. Hurvitz SA, Hurvitz CH, Sloninsky L et al. Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol 2000; 22: 527-532.
71. Hauer J, Graubner U, Konstantopoulos N et al. Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach-Merritt phenomenon using four-drug regimen. Pediatr Blood Cancer 2007; 49: 852-854.
72. Harper L, Michel JL, Enjolras O et al. Successful management of a retroperitoneal kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using alpha-interferon. Eur J Pediatr Surg 2006; 16: 369-372.
73. Hartman KR, Moncur JT, Minniti CP et al Mediastinal Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon. J Pediatr Hematol Oncol 2009; 31: 690-692.
74. Chao YH, Liang DC, Chen SH et al. Interferon-alpha for alarming hemangiomas in infants: experience of a single institution. Pediatr Int 2009; 51: 469-473.
75. Jiménez-Hernández E, Dueñas-González MT, Quintero-Curiel JL et al. Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. Dermatol Surg 2008; 34: 640-647.
76. Lindner DJ. Interferons as antiangiogenic agents. Curr Oncol Rep 2002; 4: 510-514.
77. Nevolová P, Bláhová K, Kabelka Z. Úspěchy léčby rozsáhlé hemangiomatózy u 17měsíčního dítěte po podání interferonu alfa. Ref výběr Dermatovenereol 1996; 2: 83.
78. Radzikowska E, Szczepulska-Wójcik E, Roszkowski K. Pulmonary epithelioid haemangioendothelioma - interferon 2-alpha treatment - case report. Pneumonol Alergol Pol 2008; 76: 281-285.
79. Schiavetti A, De Pasquale MD, Di Salvo S et al. Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report. Pediatr Hematol Oncol 2003; 20: 161-165.
80. Stratte EG, Tope WD, Johnson CL et al. Multimodal management of diffuse neonatal hemangiomatosis. J Am Acad Dermatol 1996; 34: 337-342.
81. Suskan E, Tekin D, Atay G et al. Airway haemangioma treated with interferon-alpha 2a. Acta Paediatr 2008; 97: 393-394.
82. Szymik-Kantorowicz S, Kobylarz K, Krysta M et al. Interferon-alpha in the treatment of high-risk haemangiomas in infants. Eur J Pediatr Surg 2005; 15: 11-16.
83. White CW. Treatment of hemangiomatosis with recombinant interferon alfa. Semin Hematol 1990; 27 (3 Suppl 4): 15-22.
84. Wu JM, Lin CS, Wang JN et al. Pulmonary cavernous hemangiomatosis treated with interferon alfa-2a. Pediatr Cardiol 1996; 17: 332-334.
85. Kaselas C, Tsikopoulos G, Papouis G et al. Intralesional administration of interferon A for the management of severe haemangiomas. Pediatr Surg Int 2007; 23: 215-218.
86. Eichler A, Ukena D, Wilkens H et al. Interferon alfa-2a in the treatment of diffuse thoracic angiomatosis in adulthood. Pneumologie 2000; 54: 243-248.
87. Sardi I, Sanzo M, Giordano F et al. Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease. Pediatr Blood Cancer 2009; 53: 464-467.
88. Takahashi A, Ogawa C, Kanazawa T et al. Remission induced by interferon alfa in a patient with massive osteolysis and extension of lymph- hemangiomatosis: a severe case of Gorham-Stout syndrome. J Pediatr Surg 2005; 40: E47-E50.
89. Or R, Feferman R, Shoshan S. Thalidomide reduces vascular density in granulomatous tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol 1998; 26: 217-221.
90. Vacca A, Scavelli C, Montefusco V et al. Thalidomide down regulates angiogenic genes in bone marrow endothelial cells of patients with multiple myeloma. J Clin Oncol 2005; 23: 5334-5346.
91. Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000; 26: 351-362.
92. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species dependent. Biochem Pharmacol 1998; 55: 1827-1834.
93. D'Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
94. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971-978.
95. Piribauer M, Czech T, Dieckmann K et al. Stabilization of a progressive hemangioblastoma under treatment with thalidomide. J Neurooncol 2004; 66: 295-299.
96. Mascarenhas RC, Sanghvi AN, Friedlander L et al. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology 2004; 67: 471-475.
97. Frei-Jones M, McKinstry RC, Perry A et al. Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. J Neurosurg Pediatr 2008; 2: 125-129.
98. Jarvi K, Roebuck DJ, Sebire NJ et al. Successful treatment of extensive infantile hemangiomatosis of the small bowel in a 3-month-old with thalidomide and somatostatin analog. J Pediatr Gastroenterol Nutr 2008; 46: 593-597.
99. Almadi M, Ghali PM, Constantin A et al. A. Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review. Can J Gastroenterol 2009; 23: 625-631.
100. Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007; 13: 5979-5984.
101. Kirkham SE, Lindley KJ, Elawad MA et al. Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide. J Pediatr Gastroenterol Nutr 2006; 42: 585-587.
102. Mimidis K, Kaliontzidou M, Tzimas T at al. Thalidomide for treatment of bleeding angiodysplasias during hemodialysis. Ren Fail 2008; 30: 1040-1041.
103. Alberto SF, Felix J, de Deus J. Thalidomide for the treatment of severe intestinal bleeding. Endoscopy 2008; 40: 788.
104. Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion 2008; 77: 131-137.
105. Dunne KA, Hill J, Dillon JF. Treatment of chronic transfusion-dependent gastric antral vascular ectasia (watermelon stomach) with thalidomide. Eur J Gastroenterol Hepatol 2006; 18: 455-456.
106. Hirri HM, Green PJ, Lindsay J. Von Willebrand's disease and angiodysplasia treated with thalidomide. Haemophilia 2006; 12: 285-286.
107. Fraiman G, Ganti AK, Potti A et al. Angiosarcoma of the small intestine: a possible role for thalidomide? Med Oncol 2003; 20: 397-402.
108. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003; 98: 221-222.
109. Dabak V, Kuriakose P, Kamboj G et al. A pilot study of thalidomide in recurrent Gl bleeding due to angiodysplasias. Dig Dis Sci 2008; 53: 1632-1635.
110. Heidt J, Langers AM, van der Meer FJ et al. Thalidomide as treatment for digestive tract angiodysplasias. Neth J Med 2006; 64: 425-428.
111. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing. Shifting the antiogenic balance. Proc Natl Acad Sci USA 2002; 99: 13243-13247.
112. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.
113. Meyerle CB, Freund KB, Iturralde D et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina 2007; 27: 451-457.
114. Ziemssen F, Voelker M, Inhoffen W et al. Combined treatment of juxtapapillary retinal capillary haemagnioma with intravitreal bevacizumab and photodynamic therapy. Eye 2007; 21: 1125-1126.
115. von Buelow M, Pape S, Hoerauf H. Systemic bevacizumab treatment of a juxtapappillary retinal haemangioma. Acta Ophthalmol Scand 2007; 85: 114-116.
116. Joeres S, Heussen FM, Treziak T et al. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1597-1602.
117. Belmont L, Zemoura L, Couderc LJ. Pulmonary epithelioid haemangioendothelioma and bevacizumab. J Thorac Oncol 2008; 3: 557-558.
118. Gilheeney SW, Scott, RM, Turner C et al. Treatment of Von Hippel Lindau associated hemangioblastoma in pediatric patients with bevacizumab (Avastin). Neurolo-Oncology 2007; 9. Abstract 168.
119. Nelson SC, Bostrom BC. Successful use of bevacizumab in live threatening steroid-resistant infantile hepatic hemangioendotelioma. Pediatr Blood Cancer 2007; 48. Abstract 611.
120. Kline RM, Buck LM. Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia. Pediatr Blood Cancer 2009; 52: 534-536.
121. Smith AR, Jane H, Margaret HK et al. Reversible bony changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome: A case report and review of the literature. Blood 2007; 110: 1323.
122. Bose P, Holter JL, Selby GB et al. Use of bevacizumab in hereditary hemorhagic telangiectasia. Blood 2008; 112 (Suppl). Abstract 3928.
123. Mitchell A, Adams LA, MacQuillan G et al. Bevacizumab reverse need for liver transplantation in hereditary hemorhagic telangiectasia. Liver Transplant 2008; 14: 210-213.
124. Smith AR, Hennessy JM, Kurth MA et al. Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome. Pediatr Blood Cancer 2008; 51: 418-420.
125. Ramasamy K, Stephen LW, Jackie C et al. Bevacizumab for POEMS syndrome. Blood 2006; 108. Abstract 366B.
126. Misri R, Kharkar V, Dandale A et al. Multiple capillary hemangiomas: a distinctive lesion of multicentric Castleman's disease and POEMS syndrome. Indian J Dermatol Venereol Leprol 2008; 74: 364-366.
127. Bellahcène A, Chaplet M, Bonjean K et al. Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells. Endothelium 2007; 14: 123-130.
128. Croucher PI, De Hendrik R, Perry MJ et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18: 482-492.
129. Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-6544.
130. Hasmim M, Bieler G, Rüegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 2007; 5: 166-173.
131. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 2003; 25: 2669-2708.
132. Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-1061.
133. Yu H, Qin A. Could local delivery of bisphosphonates be a new therapeutic choice for hemangiomas? Med Hypotheses 2009; 73: 495-497.
134. Nardone G, Rocco A, Balzano T et al. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999; 13: 1429-1436.
135. Scaglione G, Pietrini L, Russo F et al. Long acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. Aliment Pharmacol Ther 2007; 26: 935-942.
136. Nardone G, Rocco A, Balzano T et al. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999; 13: 1429-1436.
137. Loo WJ, Lanigan SW. Recent advances in laser therapy for the treatment of cutaneous vascular disorders. Lasers Med Sci 2002; 17: 9-12.
138. Winter H, Dräger E, Sterry W. Sclerotherapy for treatment of hemangiomas. Dermatol Surg 2000; 26: 105-108.
139. Colella G, Vuolo G, Siniscalchi G et al. Radiotherapy for maxillo-facial hemangiomas in children. Dental and periodontal long term effects. Minerva Stomatol 2005; 54: 509-516.
140. Kwok-Williams M, Perez Z, Squire R et al. Radiotherapy for life-threatening mediastinal hemangioma with Kasabach-Merritt syndrome. Pediatr Blood Cancer 2007; 49: 739-744.
141. Leong E, Bydder S. Use of radiotherapy to treat life-threatening Kasabach-Merritt syndrome. J Med Imaging Radiat Oncol 2009; 53: 87-91.
142. Blatný J, Štěrba J, Magnová O. Léčba život ohrožujícího krvácení u kojence s hemangiomatózou a s projevy Kasabacha-Merritové pomocí rekombinantního faktoru VIIA. Čes Slov Pediatr 2002; 57: 401-402.
143. McLaughlin ER, Morris R, Weiss SW et al. Diffuse dermal angiomatosis of the breast: response to isotretinoin. J Am Acad Dermatol 2001; 45: 462-465.
144. van Heeckeren WJ, Sanborn SL, Narayan A et al. Complication from vascular disrupting agents and angiogenesis inhibitors: aberrant control for hemostasis and thrombosis. Curr Opin Hematol 2007; 14: 468-480.